Navigation Links
Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/6/2012

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2011.

  • Total revenue for the quarter ended December 31, 2011 was $164.9 million, which included net product sales of $160.9 million.
  • Non-GAAP operating income for the quarter ended December 31, 2011 was $17.6 million, compared to a non-GAAP operating income of $22.9 million for the same period in 2010.
  • Full year non-GAAP operating income was $25.7 million, compared to a non-GAAP operating loss of $4.4 million in 2010.
  • Cash, cash equivalents, short-term investments and restricted cash totaled $214.6 million at the end of the quarter.

  • "Our strong execution in 2011 has positioned us to enter 2012 with an extraordinary opportunity to maximize shareholder value. We generated positive operating cash flow, reacquired the full rights to the exenatide franchise, expanded the approved uses for BYETTA, and, most importantly, positioned ourselves well to successfully launch BYDUREON in the U.S. following its recent approval," said Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals. "We will also work to secure a new partner for exenatide outside the U.S. to advance our commitment to diabetes patients around the world, and continue to invest strategically in value-driving opportunities while continuing our focus on financial discipline."

    Highlights of Amylin's Fourth Quarter and Recent Activities

  • Received U.S. Food and Drug Administration (FDA) approval for BYDUREON™ (exenatide extended-release for injectable suspension) – the first and only once-weekly medication approved in the U.S. and the European Union for the treatment of type 2 diabetes. BYDUREON will be available in pharmacies throughout the U.S. later this month.

  • '/>"/>
    SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
    2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
    3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
    4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
    5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
    6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
    7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
    8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
    9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
    10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
    11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... , August 27, 2015 ... convened in Boston on July ... in an effort to more fully exploit the potential ... applied to brain diseases. "As an established ... a responsibility to assume a leadership role - in ...
    (Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, Inc., ... treatment of cancer, today announced that Rachel ... company,s Board of Directors, has been appointed chief ... Eli Lilly and AstraZeneca, and also oversaw clinical ... checkpoint inhibitor, at Bristol-Myers Squibb and the development ...
    (Date:8/27/2015)... Mass. , Aug. 27, 2015 Oryzon today ... Renshaw 17th Annual Global Investment Conference in New ... ORYZON will be represented by President and CEO Carlos ... Dr. Buesa will present this information on Thursday September 10, ... Floor).  The company is completing preclinical development of its ORY-2001 ...
    Breaking Medicine Technology:New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4
    ... to Educate Women About this Common Condition, MILWAUKEE, ... at the Hyatt Regency Milwaukee hotel (333 West Kilbourn ... 7:30 pm to talk about her,experience with stress urinary ... Down There?: Breaking the Ice About SUI, a,national public ...
    ... Opiate-Like Side Effects For Several ... Months Following a Single Administration, SOUTH SAN FRANCISCO, Calif., ... that it has initiated a new,Phase 2 study of Adlea(TM) ... total knee replacement surgery, also called,total knee arthroplasty (TKA). Adlea ...
    Cached Medicine Technology:Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee 2Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee 3Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 2Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 3Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 4
    (Date:8/27/2015)... Los Angeles, CA (PRWEB) , ... August 27, 2015 , ... ... suggests that the helpfulness of a doctor is tied directly to the success of ... obese patients over a two year period, measured their weight loss over that period, ...
    (Date:8/27/2015)... ... 27, 2015 , ... Workflow in labs has greatly benefitted ... in the last decade. New features such as multiplexing, microfluidics, and integration with ... do lab managers, technicians, and researchers find handy metrics to compare and judge ...
    (Date:8/27/2015)... ... August 27, 2015 , ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. ... Aging Expo in Denver, Colorado on Saturday, August 29, 2015 at the Marriott DTC, ... outlets as health authorities, and will present a two part seminar entitled, “How to ...
    (Date:8/27/2015)... ... August 27, 2015 , ... About 10 ... slammed into the Gulf Coast, killing more than 1,800 people, displacing hundreds of ... a Georgia State University study. , While most people don’t develop persistent depression ...
    (Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a leading provider of ... is ICD-10 ready and available to all clients. All Krames Patient Education content ... are more targeted and return a more comprehensive data set of content than ...
    Breaking Medicine News(10 mins):Health News:Article on Physician Influence on Weight Loss Highlights the Importance of a Doctor Who Cares, says Dr. Feiz & Associates 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3
    ... type of anti-inflammatory drugs could be better for older ... older people to relieve arthritis symptoms. The problem is ... gastrointestinal problems. A specialized group of NSAIDs called COX-2 ... with heart complications. ,Researchers looked more closely at ...
    ... smoking actually helps arteries stay open following a procedure ... who conducted the study say they do not recommend ... of carbon monoxide in the blood stream may be ... ,Peripheral artery disease(PAD) is a narrowing or blockage ...
    ... level is a marker to help determine if a man ... prevalence of men with prostate cancer who had a PSA ... the Prostate Cancer Prevention Trial. Among 9,459 men in the ... than four or an abnormal rectal examination. For this research, ...
    ... shows pregnant women with asthma can reduce their risk of ... // mothers who ate oily fish, such as salmon and ... children with asthma. In fact, researchers say the more oily ... to develop asthma. Children with non-asthmatic mothers did not benefit ...
    ... recent study researchers say, the ancient Eastern tradition of yoga ... part in yoga classes reported better sleep quality than those ... 39 lymphoma patients who were either undergoing treatment or who ... patients were assigned to the yoga classes while the other ...
    ... one of the most worrisome long-term side effects of high-dose ... identify biochemical markers that might indicate which patients are at ... ,Troponin I is a protein present only in ... heart muscle injury that is used to diagnose and treat ...
    Cached Medicine News:
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: